Necrotizing Enterocolitis (NEC) - Epidemiology Forecast - 2032

Key Highlights:

• The risk of necrotizing enterocolitis increases with decreasing gestational age and is greatest in infants less than 28 weeks gestation. Necrotizing enterocolitis remains a significant burden with high mortality across decades, despite advances in neonatal intensive care.
• The incidence of NEC is lower in Japan (~2% of VLBW infants) than in other countries. The low rate of NEC can be attributed to the nutrition management of extremely preterm infants in Japan, characterized by the promotion of breastfeeding, early minimal enteral feeding, routine glycerin enema, and probiotics administration.
• IBP-9414 is the only medication being developed to reduce/prevent the incidence of NEC in premature babies (=1,500 g). Therefore, our analysis takes into account preterm babies who are at risk of developing NEC. Live birth rates are declining in certain European countries nations and Japan.

DelveInsight's "Necrotizing Enterocolitis (NEC) - Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of necrotizing enterocolitis historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Necrotizing Enterocolitis Disease Understanding:

Necrotizing Enterocolitis Overview

Necrotizing enterocolitis is a common and devastating gastrointestinal emergency that primarily affects premature infants worldwide in neonatal intensive care units. At birth, neonates are rapidly exposed to environmental bacteria through maternal vaginal flora and enteral feedings. Preterm neonates experience delayed and often inappropriate colonization, leading to increased inflammatory responses and abnormal bacterial glycosylation patterns.

Necrotizing Enterocolitis Diagnosis

Steps are taken to prevent the infant from getting infections after a premature baby is born. If these preventive measures are unsuccessful, the baby can experience symptoms like a swollen abdomen, tiredness, and breathing pauses. Doctors conduct tests such as a complete blood count, a C-reactive protein test, and x-rays to diagnose the condition. After these tests, it is confirmed that the baby has necrotizing enterocolitis.

Further details related to diagnosis are provided in the report…

Necrotizing Enterocolitis Epidemiology

As the market is derived using a patient-based model, the necrotizing enterocolitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of preterm infants by birth weight (=1,500 g) and total incident cases of necrotizing enterocolitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

• The total number of incident cases of preterm infants by birth weight (=1,500 g) in the 7MM was ~94,000 in 2022. As per the estimate, the incident cases of preterm infants by birth weight (=1,500 g) in the 7MM are anticipated to increase during the study period of 2019-2032.
• The incidence of NEC is currently declining. Preterm newborns are increasingly being treated with probiotics, although the facts supporting this practice do not meet the high standards of the pharmaceutical and healthcare industries. A reduction in the number of NEC incident cases in the 7MM is expected with the introduction of pharma-grade probiotics to the market.
• The total number of incident cases of necrotizing enterocolitis in the US was ~4,000 in 2022 and is expected to decline during the forecast period.
• Among the EU4, Germany accounted for the highest number of incident cases of preterm infants by birth weight (=1,500 g), followed by France, whereas Spain accounted for the lowest cases in 2022.

KOL Views:

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the necrotizing enterocolitis evolving preventive treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility, including pulmonologists, HCPs, Physicians, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Nationwide Children's Hospital, Columbus, OH, the United States, University Hospitals Dorset NHS Foundation Trust, the United Kingdom, Department of Pediatrics, North Shore University Health System, Evanston, Illinois, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or necrotizing enterocolitis market trends. This will support the clients in potential upcoming novel prophylactic treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of necrotizing enterocolitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Necrotizing Enterocolitis Report Insights

• Patient population
• Country-wise epidemiology distribution
• Incident cases of necrotizing enterocolitis

Necrotizing Enterocolitis Report Key Strengths

• Ten years forecast
• The 7MM coverage
• Necrotizing enterocolitis epidemiology segmentation

Necrotizing Enterocolitis Report Assessment

• Current diagnostic practices

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of necrotizing enterocolitis?
• What will be the growth opportunities across the 7MM concerning the patient population with necrotizing enterocolitis?
• What is the historical and forecasted necrotizing enterocolitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why are incident cases of preterm infants by birth weight (=1,500 g) declining in Germany?
• Why are incident cases of necrotizing enterocolitis declining in the 7MM?

Reasons to Buy:

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• A detailed overview of preterm infants by birth weight (=1,500 g) cases of necrotizing enterocolitis.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.